How I treat heparin-induced thrombocytopenia

Blood

Volumn 119, Issue 10, 2012, Pages 2209-2218

  Cuker, Adam ^a   Cines, Douglas B ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; ANTICOAGULANT AGENT; ARGATROBAN; BLOOD CLOTTING FACTOR 10A INHIBITOR; CARBON 14; DANAPAROID; DESULFATOHIRUDIN; FONDAPARINUX; HEPARIN; HIRULOG; LEPIRUDIN; LOW MOLECULAR WEIGHT HEPARIN; SEROTONIN; THROMBIN INHIBITOR; THROMBOCYTE FACTOR 4;

ADOLESCENT; AGED; ALGORITHM; ANTICOAGULANT THERAPY; ARTERY THROMBOSIS; ASSAY; BLEEDING; CARDIOPULMONARY BYPASS; CHILD; CLINICAL ASSESSMENT; CLINICAL PRACTICE; COMPARTMENT SYNDROME; CONTINUOUS INFUSION; CRITICALLY ILL PATIENT; DEEP VEIN THROMBOSIS; DIAGNOSTIC ACCURACY; DIAGNOSTIC ERROR; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG COST; DRUG EFFICACY; DRUG FORMULATION; DRUG HALF LIFE; DRUG MEGADOSE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HEMATOLOGICAL PARAMETERS; HEMODIALYSIS; HEMODIALYSIS PATIENT; HEPARIN INDUCED THROMBOCYTOPENIA; HOSPITAL PATIENT; HUMAN; IMMUNOASSAY; INTERNATIONAL NORMALIZED RATIO; LABORATORY DIAGNOSIS; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; META ANALYSIS (TOPIC); ORTHOPEDIC SURGERY; PARTIAL THROMBOPLASTIN TIME; PATIENT MONITORING; PERIODONTITIS; PRACTICE GUIDELINE; PREGNANCY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK BENEFIT ANALYSIS; RISK FACTOR; SCORING SYSTEM; SEROCONVERSION; SEROTONIN RELEASE; SURGICAL PATIENT; SYSTEMATIC REVIEW (TOPIC); THROMBOCYTE; THROMBOCYTE ACTIVATION; THROMBOCYTE COUNT; THROMBOCYTE TRANSFUSION; THROMBOCYTOPENIA; THROMBOSIS; TREATMENT DURATION; TREATMENT OUTCOME; VENOUS THROMBOEMBOLISM;

EID: 84858057979     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2011-11-376293     Document Type: Review

References (106)

1. Amiral J, Bridey F, Dreyfus M, et al. Platelet factor 4 complexed to heparin is the target for antibodies generated in heparin-induced thrombocytopenia. Thromb Haemost. 1992;68(1):95- 96.
2. Weissmann RE, Tobin RW. Arterial embolism occurring during systemic heparin therapy. AMA Arch Surg. 1958;76(2):219-227.
3. Alving BM. How I treat heparin-induced thrombocytopenia and thrombosis. Blood. 2003;101(1): 31-37. (Pubitemid 36025883)
4. Warkentin TE. Think of HIT. Hematology Am Soc Hematol Educ Program. 2006:408-414.
5. Cuker A. Heparin-induced thrombocytopenia (HIT) in 2011: an epidemic of overdiagnosis. Thromb Haemost. 2011;106(6):993-994.
6. Warkentin TE. HIT paradigms and paradoxes. J Thromb Haemost. 2011;9(suppl 1):105-117.
7. Martel N, Lee J, Wells PS. Risk for heparininduced thrombocytopenia with unfractionated and low-molecular-weight heparin thromboprophylaxis: a meta-analysis. Blood. 2005;106(8): 2710-2715. (Pubitemid 41510744)
8. Warkentin TE, Sheppard JA, Sigouin CS, Kohlmann T, Eichler P, Greinacher A. Gender imbalance and risk factor interactions in heparininduced thrombocytopenia. Blood. 2006;108(9): 2937-2941.
9. Warkentin TE, Cook RJ, Marder VJ, et al. Antiplatelet factor 4/heparin antibodies in orthopedic surgery patients receiving antithrombotic prophylaxis withfondaparinux or enoxaparin. Blood. 2005;106(12): 3791-3796. (Pubitemid 41739014)
10. Smythe MA, Koerber JM, Mattson JC. The incidence of recognized heparin-induced thrombocytopenia in a large, tertiary care teaching hospital. Chest. 2007;131(6):1644-1649. (Pubitemid 46981615)
11. Gallus AS, Goodall KT, BeswickW, Chesterman CN. Heparin-associated thrombocytopenia: case report and prospective study. Aust NZ J Med. 1980;10(1): 25-31. (Pubitemid 10144147)
12. Lindhoff-Last E, Nakov R, Misselwitz F, Breddin HK, Bauersachs R. Incidence and clinical relevance of heparin-induced antibodies in patients with deep vein thrombosis treated with unfractionated or low-molecular weight heparin. Br J Haematol. 2002;118(4): 1137-1142. (Pubitemid 35025982)
13. Stein PD, Hull RD, Matta F, YaekoubAY, Liang J. Incidence of thrombocytopenia in hospitalized patients with venous thromboembolism. Am J Med. 2009; 122(10):919-930.
14. Bauer TL, Arepally G, Konkle BA, et al. Prevalence of heparin-associated antibodies without thrombosis in patients undergoing cardiopulmonary bypass surgery. Circulation. 1997;95(5): 1242-1246. (Pubitemid 27097836)
15. Warkentin TE, Sheppard JA, Horsewood P, Simpson PJ, Moore JC, Kelton JG. Impact of the patient population on the risk of heparin-induced thrombocytopenia. Blood. 2000;96(5):1703-1708. (Pubitemid 30661052)
16. Warkentin TE, Levine MN, Hirsh J, et al. Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. N Engl J Med. 1995;332(20):1330- 1335.
17. Lubenow N, Hinz P, Thomaschewski S, et al. The severity of trauma determines the immune response to PF4/heparin and the frequency of heparin- induced thrombocytopenia. Blood. 2010; 115(9):1797-1803.
18. Crowther MA, Cook DJ, Albert M, et al. The 4Ts scoring system for heparin-induced thrombocytopenia in medical-surgical intensive care unit patients. J Crit Care. 2010;25(2):287-293.
19. Hutchison CA, Dasgupta I. National survey of heparin-induced thrombocytopenia in the haemodialysis population of the UK population. Nephrol Dial Transplant. 2007;22(6):1680-1684. (Pubitemid 47073768)
20. Sanson BJ, Lensing AW, Prins MH, et al. Safety of low-molecular-weight heparin in pregnancy: a systematic review. Thromb Haemost. 1999;81(5): 668-672. (Pubitemid 29216546)
21. Greinacher A, Holtfreter B, Krauel K, et al. Association of natural antiplatelet factor 4/heparin antibodies with periodontal disease. Blood. 2011; 118(5):1395-1401.
22. Oliveira GB, Crespo EM, Becker RC, et al. Incidence and prognostic significance of thrombocytopenia in patients treated with prolonged heparin therapy. Arch Intern Med. 2008;168(1):94-102.
23. Warkentin TE, Kelton JG. Temporal aspects of heparin-induced thrombocytopenia. N Engl J Med. 2001;344(17):1286-1292. (Pubitemid 32372963)
24. Rice L, Attisha WK, Drexler A, Francis JL. Delayed-onset heparin-induced thrombocytopenia. Ann Intern Med. 2002;136(3):210-215. (Pubitemid 34118121)
25. Warkentin TE, Makris M, Jay RM, Kelton JG. A spontaneous prothrombotic disorder resembling heparin-induced thrombocytopenia. Am J Med. 2008;121(7):632-636. (Pubitemid 351876183)
26. Warkentin TE. Clinical presentation of heparin-induced thrombocytopenia. Semin Hematol. 1998;35(4 suppl):9-16. (Pubitemid 28549557)
27. Warkentin TE, Roberts RS, Hirsh J, Kelton JG. An improved definition of immune heparin-induced thrombocytopenia in postoperative orthopedic patients. Arch Intern Med. 2003;163(20):2518-2524. (Pubitemid 37385796)
28. Greinacher A, Janssens U, Berg G, et al. Lepirudin (recombinant hirudin) for parenteral anticoagulation in patients with heparin-induced thrombocytopenia: Heparin-Associated Thrombocytopenia Study (HAT) investigators. Circulation. 1999;100(6):587-593. (Pubitemid 29379746)
29. Greinacher A, Farner B, Kroll H, Kohlmann T, Warkentin TE, Eichler P. Clinical features of heparin-induced thrombocytopenia including risk factors for thrombosis: a retrospective analysis of 408 patients. Thromb Haemost. 2005;94(1):132- 135.
30. Warkentin TE, Kelton JG. A 14-year study of heparin- induced thrombocytopenia. Am J Med. 1996; 101(5):502-507. (Pubitemid 126335970)
31. Rosenberger LH, Smith PW, Sawyer RG, Hanks JB, Adams RB, Hedrick TL. Bilateral adrenal hemorrhage: the unrecognized cause of hemodynamic collapse associated with heparin-induced thrombocytopenia. Crit Care Med. 2011;39(4):833-838.
32. Hong AP, Cook DJ, Sigouin CS, Warkentin TE. Central venous catheters and upper-extremity deep-vein thrombosis complicating immune heparin- induced thrombocytopenia. Blood. 2003; 101(8):3049-3051. (Pubitemid 36857994)
33. Warkentin TE, Roberts RS, Hirsh J, Kelton JG. Heparin-induced skin lesions and other unusual sequelae of the heparin-induced thrombocytopenia syndrome: a nested cohort study. Chest. 2005;127(5):1857-1861. (Pubitemid 46218820)
34. Schindewolf M, Kroll H, Ackermann H, et al. Heparin-induced non-necrotizing skin lesions: rarely associated with heparin-induced thrombocytopenia. J Thromb Haemost. 2010;8(7):1486- 1491.
35. Hui P, Cook DJ, Lim W, Fraser GA, Arnold DM. The frequency and clinical significance of thrombocytopenia complicating critical illness: a systematic review. Chest. 2011;139(2):271-278.
36. Nader ND, Khadra WZ, Reich NT, Bacon DR, Salerno TA, Panos AL. Blood product use in cardiac revascularization: comparison of on- and off-pump techniques. Ann Thorac Surg. 1999; 68(5):1640-1643.
37. Selleng S, Malowsky B, Strobel U, et al. Early-onset and persisting thrombocytopenia in postcardiac surgery patients is rarely due to heparin-induced thrombocytopenia, even when antibody tests are positive. J Thromb Haemost. 2010;8(1): 30-36.
38. Lillo-Le Louet A, Boutouyrie P, Alhenc-Gelas M, et al. Diagnostic score for heparin-induced thrombocytopenia after cardiopulmonary bypass. J Thromb Haemost. 2005;2(11):1882-1888.
39. Lo GK, Juhl D, Warkentin TE, Sigouin CS, Eichler P, Greinacher A. Evaluation of a pretest clinical score (4 T's) for the diagnosis of heparin-induced thrombocytopenia in two clinical settings. J Thromb Haemost. 2006;4(4):759-765.
40. Cuker A, Arepally G, Crowther MA, et al. The HIT Expert Probability (HEP) score: a novel pre-test probability model for heparin-induced thrombocytopenia based on broad expert opinion. J Thromb Haemost. 2010;8(12):2642-2650.
41. Crowther MA, Langevin S, Cooper JL, et al. Laboratory HIT testing in critically ill patients [abstract]. Am Soc Hematol Educ Program. 2011; 18(21):Abstract 198.
42. Berry C, Tcherniantchouk O, Ley EJ, et al. Overdiagnosis of heparin-induced thrombocytopenia in surgical ICU patients. J Am Coll Surg. 2011; 213(1):10-17.
43. McGinn TG, Guyatt GH, Wyer PC, Naylor CD, Stiell IG, Richardson WS. Users' guides to the medical literature: XXII. How to use articles about clinical decision rules. Evidence-Based Medicine Working Group. JAMA. 2000;284(1):79-84. (Pubitemid 30445665)
44. Pouplard C, Amiral J, Borg JY, Laporte-Simitsidis S, Delahousse B, Gruel Y. Decision analysis for use of platelet aggregation test, carbon 14-serotonin release assay, and heparin-platelet factor 4 enzyme-linked immunosorbent assay for diagnosis of heparin- induced thrombocytopenia. Am J Clin Pathol. 1999;111(5):700-706. (Pubitemid 29200959)
45. Amiral J. Antigens involved in heparin-induced thrombocytopenia. Semin Hematol. 1999;36(1 suppl 1):7-11. (Pubitemid 29045504)
46. Sachs UJ, von Hesberg J, Santoso S, Bein G, Bakchoul T. Evaluation of a new manoparticlebased lateral flow immunoassay for the exclusion of heparin-induced thrombocytopenia. Thromb Haemost. 2011;106(6):1197-1202.
47. Davidson SJ, Ortel TL, Smith LJ. Performance of a new, rapid, automated immunoassay for the detection of antiplatelet factor 4/heparin complex antibodies. Blood Coagul Fibrinolysis. 2011; 22(4):340-344.
48. Lo GK, Sigouin CS, Warkentin TE. What is the potential for overdiagnosis of heparin-induced thrombocytopenia? Am J Hematol. 2007;82(12): 1037-1043. (Pubitemid 350209843)
49. Pauzner R, Greinacher A, Selleng K, Althaus K, Shenkman B, Seligsohn U. False-positive tests for heparin-induced thrombocytopenia in patients with antiphospholipid syndrome and systemic lupus erythematosus. J Thromb Haemost. 2009; 7(7):1070-1074.
50. Sikara MP, Routsias JG, Samiotaki M, Panayotou G, Moutsopoulos HM, Vlachoyiannopoulos PG. beta2 glycoprotein I (beta2GPI) binds platelet factor 4 (PF4): implications for the pathogenesis of antiphospholipid syndrome. Blood. 2010;115(3):713-723.
51. Demma LJ, Winkler AM, Levy JH. A diagnosis of heparin-induced thrombocytopenia with combined clinical and laboratory methods in cardiothoracic surgical intensive care unit patients. Anesth Analg. 2011;113(4):697-702.
52. Warkentin TE, Sheppard JI, Moore JC, Sigouin CS, Kelton JG. Quantitative interpretation of optical density measurements using PF4-dependent enzymeimmunoassays. J Thromb Haemost. 2008;6(8): 1304-1312. (Pubitemid 352016309)
53. Denys B, Stove V, Philippe J, Devreese K. A clinical- laboratory approach contributing to a rapid and reliable diagnosis of heparin-induced thrombocytopenia. Thromb Res. 2008;123(1):137-145.
54. Zwicker JI, Uhl L, Huang WY, Shaz BH, Bauer KA. Thrombosis and ELISA optical density values in hospitalized patients with heparin-induced thrombocytopenia. J Thromb Haemost. 2004;2(12):2133-2137. (Pubitemid 40185772)
55. Bakchoul T, Giptner A, Najaoui A, Bein G, Santoso S, Sachs UJ. Prospective evaluation of PF4/heparin immunoassays for the diagnosis of heparin-induced thrombocytopenia. J Thromb Haemost. 2009;7(8):1260-1265.
56. Cuker A, Ortel TL. ASH evidence-based guidelines: is the IgG-specific anti-PF4/heparin ELISA superior to the polyspecific ELISA in the laboratory diagnosis of HIT? Hematology Am Soc Hematol Educ Program. 2009;2009:250-252.
57. Whitlatch NL, Kong DF, Metjian AD, Arepally GM, Ortel TL. Validation of the high-dose heparin confirmatory step for the diagnosis of heparin-induced thrombocytopenia. Blood. 2010;116(10): 1761-1766.
58. Althaus K, Strobel U,Warkentin TE, Greinacher A. Combined use of the high heparin step and optical density to optimize diagnostic sensitivity and specificity of an anti-PF4/heparin enzyme-immunoassay. Thromb Res. 2011;128(3):256-260.
59. Sheridan D, Carter C, Kelton JG. A diagnostic test for heparin-induced thrombocytopenia. Blood. 1986;67(1):27-30. (Pubitemid 16167006)
60. Greinacher A, Michels I, Kiefel V, Mueller- Eckhardt C. A rapid and sensitive test for diagnosing heparin-associated thrombocytopenia. Thromb Haemost. 1991;66(6):734-736.
61. Price EA, Hayward CP, Moffat KA, Moore JC, Warkentin TE, Zehnder JL. Laboratory testing for heparin-induced thrombocytopenia is inconsistent in North America: a survey of North American specialized coagulation laboratories. Thromb Haemost. 2007;98(6):1357-1361. (Pubitemid 350239110)
62. Greinacher A, Eichler P, Lubenow N, Kwasny H, Luz M. Heparin-induced thrombocytopenia with thromboembolic complications: a meta-analysis of 2 prospective trials to assess the value of parenteral treatment with lepirudin and its therapeutic aPTT range. Blood. 2000;96(3):846-851. (Pubitemid 30616845)
63. Warkentin TE, Greinacher A, Koster A, et al. Treatment and prevention of heparin-induced thrombocytopenia: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Ed). Chest. 2008;133(suppl):340S-380S. (Pubitemid 351892970)
64. Cuker A. Current and emerging therapeutics for heparin-induced thrombocytopenia. Semin Thromb Hemost. 2012;38(1):31-37.
65. Lewis BE, Wallis DE, Leya F, et al. Argatroban anticoagulation in patients with heparin-induced thrombocytopenia. Arch Intern Med. 2003; 163(15):1849-1856. (Pubitemid 36960936)
66. Lewis BE, Wallis DE, Berkowitz SD, et al. Argatroban anticoagulation therapy in patients with heparin-induced thrombocytopenia. Circulation. 2001;103(14):1838-1843. (Pubitemid 32328395)
67. Walenga JM, Jeske WP, Wood JJ, Ahmad S, Lewis BE, Bakhos M. Laboratory tests for heparin- induced thrombocytopenia: a multicenter study. Semin Hematol. 1999;36(1 suppl 1):22-28. (Pubitemid 29045507)
68. Lewis BE, Wallis DE, Hursting MJ, Levine RL, Leya F. Effects of argatroban therapy, demographic variables, and platelet count on thrombotic risk in heparin-induced thrombocytopenia. Chest. 2006;129(6):1407-1416. (Pubitemid 43894967)
69. Beiderlinden M, Treschan TA, Gorlinger K, Peters J. Argatroban anticoagulation in critically ill patients. Ann Pharmacother. 2007;41(5):749- 754.
70. Greinacher A, Volpel H, Janssens U, et al. Recombinant hirudin (lepirudin) provides safe and effective anticoagulation in patients with heparin-induced thrombocytopenia: a prospective study. Circulation. 1999;99(1):73-80. (Pubitemid 29035960)
71. Lubenow N, Eichler P, Lietz T, et al. Lepirudin in patients with heparin-induced thrombocytopenia: results of the third prospective study (HAT-3) and a combined analysis of HAT-1, HAT-2, and HAT-3. J Thromb Haemost. 2005;3(11):2428-2436. (Pubitemid 41727158)
72. Tardy B, Lecompte T, Boelhen F, et al. Predictive factors for thrombosis and major bleeding in an observational study in 181 patients with heparin-induced thrombocytopenia treated with lepirudin. Blood. 2006;108(5):1492-1496. (Pubitemid 44316113)
73. Song X, Huhle G, Wang L, Hoffmann U, Harenberg J. Generation of antihirudin antibodies in heparin-induced thrombocytopenic patients treated with r-hirudin. Circulation. 1999;100(14): 1528-1532. (Pubitemid 29461465)
74. Eichler P, Friesen HJ, Lubenow N, Jaeger B, Greinacher A. Antihirudin antibodies in patients with heparin-induced thrombocytopenia treated with lepirudin: incidence, effects on aPTT, and clinical relevance. Blood. 2000;96(7):2373-2378.
75. Greinacher A, Lubenow N, Eichler P. Anaphylactic and anaphylactoid reactions associated with lepirudin in patients with heparin-induced thrombocytopenia. Circulation. 2003;108(17):2062-2065. (Pubitemid 37337579)
76. Bittl JA, Chaitman BR, Feit F, Kimball W, Topol EJ. Bivalirudin versus heparin during coronary angioplasty for unstable or postinfarction angina: final report reanalysis of the Bivalirudin Angioplasty Study. Am Heart J. 2001;142(6):952- 959.
77. Dyke CM, Smedira NG, Koster A, et al. A comparison of bivalirudin to heparin with protamine reversal in patients undergoing cardiac surgery with cardiopulmonary bypass: the EVOLUTION- ON study. J Thorac Cardiovasc Surg. 2006; 131(3):533-539.
78. Koster A, Spiess B, Jurmann M, et al. Bivalirudin provides rapid, effective, and reliable anticoagulation during off-pump coronary revascularization: results of the "EVOLUTION OFF" trial. Anesth Analg. 2006;103(3):540-544. (Pubitemid 44542900)
79. Kiser TH, Fish DN. Evaluation of bivalirudin treatment for heparin-induced thrombocytopenia in critically ill patients with hepatic and/or renal dysfunction. Pharmacotherapy. 2006;26(4):452-460.
80. Boyce SW, Bandyk DF, Bartholomew JR, Frame JN, Rice L. A randomized, open-label pilot study comparing desirudin and argatroban in patients with suspected heparin-induced thrombocytopenia with or without thrombosis. Am J Ther. 2011;18(1):14-22.
81. Chong BH, Gallus AS, Cade JF, et al. Prospective randomised open-label comparison of danaparoid with dextran 70 in the treatment of heparin-induced thrombocytopaenia with thrombosis: a clinical outcome study. Thromb Haemost. 2001; 86(5):1170-1175. (Pubitemid 33064563)
82. Farner B, Eichler P, Kroll H, Greinacher A. A comparison of danaparoid and lepirudin in heparin-induced thrombocytopenia. Thromb Haemost. 2001;85(6):950-957. (Pubitemid 32573742)
83. Magnani HN, Gallus A. Heparin-induced thrombocytopenia (HIT): a report of 1,478 clinical outcomes of patients treated with danaparoid (Orgaran) from 1982 to mid-2004. Thromb Haemost. 2006;95(6):967-981. (Pubitemid 43933754)
84. Warkentin TE. Fondaparinux: does it cause HIT? Can it treat HIT? Expert Rev Hematol. 2010;3(5): 567-581.
85. Goldfarb MJ, Blostein M. Fondaparinux in acute heparin-induced thrombocytopenia: a case series. J Thromb Haemost. 2011;9(12):2501-2503.
86. Warkentin TE, Pai M, Sheppard JI, Schulman S, Spyropoulos AC, Eikelboom JW. Fondaparinux treatment of acute heparin-induced thrombocytopenia confirmed by serotonin-release assay: a 30-month, 16-patient case series. J Thromb Haemost. 2011;9(12):2389-2396.
87. Warkentin TE, Davidson BL, Buller HR, et al. Prevalence and risk of pre-existing heparin-induced thrombocytopenia antibodies in patients with acute venous thromboembolism. Chest. 2011;140(2):366-373.
88. Motokawa S, Torigoshi T, Maeda Y, et al. IgGclass anti-PF4/heparin antibodies and symptomatic DVT in orthopedic surgery patients receiving different antithromboembolic prophylaxis therapeutics. BMC Musculoskelet Disord. 2011;12:22.
89. To L, Schillig JM, Desmet BD, Kuriakose P, Szandzik EG, Kalus JS. Impact of a pharmacist-directed anticoagulation service on the quality and safety of heparin-induced thrombocytopenia management. Ann Pharmacother. 2011;45(2): 195-200.
90. Lewis BE, Aranda C, Lewis M, Hoppensteadt D, Walenga JM, Fareed J. Unlike heparins newer oral anticoagulants do not interact with HIT antibodies and maybe useful in the long-term anticoagulant management of heparin compromised patients [abstracts]. Am Soc Hematol Educ Program. 2011;118(21):Abstract 2317.
91. Hursting MJ, Verme-Gobboney CN. Risk factors for major bleeding in patients with heparin-induced thrombocytopenia treated with argatroban: a retrospective study. J Cardiovasc Pharmacol. 2008;52(6):561-566.
92. Krauel K, Hackbarth C, Furll B, Greinacher A. Heparin-induced thrombocytopenia: in vitro studies on the interaction of dabigatran, rivaroxaban, and low-sulfated heparin, with platelet factor 4 and anti-PF4/heparin antibodies. Blood. 2012; 119(5):1248-1255.
93. Sachais BS, Rux AH, Hinds JL, Rux JJ. Rational design and characterization of platelet factor 4 antagonists [abstract]. Am Soc Hematol Educ Program. 2010;116(21):Abstract 724.
94. Reilly MP, Sinha U, Andre P, et al. PRT-060318, a novel syk inhibitor, prevents heparin-induced thrombocytopenia and thrombosis in a transgenic mouse model. Blood. 2011;117(7):2241-2246.
95. Lhermusier T, van Rottem J, Garcia C, et al. The Syk-kinase inhibitor R406 impairs platelet activation and monocyte tissue factor expression triggered by heparin-PF4 complex directed antibodies. J Thromb Haemost. 2011;9(10):2067-2076.
96. Stolla M, Stefanini L, Andre P, et al. CalDAG-GEFI deficiency protects mice in a novel model of FcgammaRIIA-mediated thrombosis and thrombocytopenia. Blood. 2011;118(4):1113-1120.
97. Wilke T, Tesch S, Scholz A, Kohlmann T, Greinacher A. The costs of heparin-induced thrombocytopenia: a patient-based cost of illness analysis. J Thromb Haemost. 2009;7(5):766-773.
98. Warkentin TE, Elavathil LJ, Hayward CP, Johnston MA, Russett JI, Kelton JG. The pathogenesis of venous limb gangrene associated with heparin-induced thrombocytopenia. Ann Intern Med. 1997;127(9):804-812. (Pubitemid 27465548)
99. Sheth SB, DiCicco RA, Hursting MJ, Montague T, Jorkasky DK. Interpreting the International Normalized Ratio (INR) in individuals receiving argatroban and warfarin. Thromb Haemost. 2001; 85(3):435-440. (Pubitemid 32233014)
100. Tardy B, Tardy-Poncet B, Fournel P, Venet C, Jospe R, Dacosta A. Lower limb veins should be systematically explored in patients with isolated heparin-induced thrombocytopenia. Thromb Haemost. 1999;82(3):1199-1200. (Pubitemid 29419746)
101. Refaai MA, Chuang C, Menegus M, Blumberg N, Francis CW. Outcomes after platelet transfusion in patients with heparin-induced thrombocytopenia. J Thromb Haemost. 2010;8(6):1419-1421.
102. Hopkins CK, Goldfinger D. Platelet transfusions in heparin-induced thrombocytopenia: a report of four cases and review of the literature. Transfusion. 2008;48(10):2128-2132.
103. Potzsch B, Klovekorn WP, Madlener K. Use of heparin during cardiopulmonary bypass in patients with a history of heparin-induced thrombocytopenia. N Engl J Med. 2000;343(7):515. (Pubitemid 30646499)
104. Selleng S, Haneya A, Hirt S, Selleng K, Schmid C, Greinacher A. Management of anticoagulation in patients with sub acute heparin-induced thrombocytopenia scheduled for heart transplantation. Blood. 2008;112(10):4024-4027.
105. Asmis LM, Segal JB, Plantinga LC, et al. Heparininduced antibodies and cardiovascular risk in patients on dialysis. Thromb Haemost. 2008;100(3): 498-504.
106. Carrier M, Knoll GA, Kovacs MJ, Moore JC, Fergusson D, Rodger MA. The prevalence of antibodies to the platelet factor 4-heparin complex and association with access thrombosis in patients on chronic hemodialysis. Thromb Res. 2007;120(2):215-220. (Pubitemid 46754417)